These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 619324)

  • 21. [Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].
    Senn HJ; Lei D; Castaño-Almendral A; Brunner KW; Martz G; Obrecht P; Melchert F; Rhomberg W
    Schweiz Med Wochenschr; 1980 Aug; 110(33):1202-8. PubMed ID: 7423163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin.
    Park RC; Blom J; Disaia PJ; Lagasse LD; Blessing JA
    Cancer; 1980 May; 45(10):2529-42. PubMed ID: 7378989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma.
    Decker DG; Fleming TR; Malkasian GD; Webb MJ; Jeffries JA; Edmonson JH
    Obstet Gynecol; 1982 Oct; 60(4):481-7. PubMed ID: 6889714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy of ovarian cancer: past and present.
    Young RC
    Semin Oncol; 1975 Sep; 2(3):267-76. PubMed ID: 827024
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
    Miller AB; Klaassen DJ; Boyes DA; Dodds DJ; Gerulath A; Kirk ME; Levitt M; Pearson JG; Wall C
    Can Med Assoc J; 1980 Sep; 123(5):365-71. PubMed ID: 7020903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quadrichemotherapy for advanced ovarian carcinoma.
    Kessinger A; Foley JF; Lemon HM
    Obstet Gynecol; 1976 Aug; 48(2):134-6. PubMed ID: 940644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer.
    Mougenot P; Fabbro M; Bressolle F; Pouessel D; Culine S; Pinguet F
    Oncol Rep; 2006 Jan; 15(1):237-41. PubMed ID: 16328062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
    Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.
    Burger RA; DiSaia PJ; Roberts JA; O'rourke M; Gershenson DM; Homesley HD; Lichtman SM; Barnes W; Moore DH; Monk BJ
    Gynecol Oncol; 1999 Feb; 72(2):148-53. PubMed ID: 10021293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histologic grade in advanced ovarian cancer.
    Ozols RF; Garvin AJ; Costa J; Simon RM; Young RC
    Cancer Treat Rep; 1979 Feb; 63(2):255-63. PubMed ID: 109199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
    Pouillart P; Bretaudeau B; Palangie T; Jouve M; Garcia-Giralt E; Asselain B
    Bull Cancer; 1982; 69(5):434-42. PubMed ID: 6891903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.
    Piver MS; Barlow JJ; Bhattacharya M
    Cancer Treat Rep; 1979 Feb; 63(2):265-7. PubMed ID: 376133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.